Management of Hypertension in Prostate Cancer Patients on Abiraterone and Prednisone
Monitor blood pressure monthly and treat hypertension aggressively with standard antihypertensive agents while continuing abiraterone therapy, as the hypertension is a manageable mineralocorticoid excess effect that does not require discontinuation of cancer treatment unless BP exceeds 160/100 mmHg despite treatment. 1
Understanding the Mechanism
Abiraterone inhibits CYP17A1, blocking both testosterone and cortisol synthesis. The resulting cortisol deficiency triggers compensatory ACTH elevation, which drives production of mineralocorticoid precursors (deoxycorticosterone, corticosterone), causing hypertension, hypokalemia, and peripheral edema 2, 1. The concurrent prednisone 5 mg twice daily is intended to suppress ACTH and mitigate these effects, but breakthrough mineralocorticoid excess occurs in approximately 22% of patients, with severe hypertension in 4% 2.
Monitoring Requirements
Monthly monitoring is mandatory and should include 1:
- Blood pressure measurements
- Serum potassium levels
- Liver function tests (AST/ALT)
- Phosphate levels
- Symptom-directed cardiac assessment, particularly in patients with pre-existing cardiovascular disease
Treatment Algorithm for Hypertension
Step 1: Optimize Prednisone Dosing
Recent evidence suggests prednisone 5 mg twice daily is superior to 5 mg once daily for preventing mineralocorticoid excess. A 2024 study of 1,057 patients demonstrated that twice-daily dosing reduced the cumulative hazard of hypertension and/or hypokalemia (HR 0.79, p=0.002) without increasing metabolic side effects 3. If your patient is on once-daily prednisone, consider switching to 5 mg twice daily as the first intervention.
Step 2: Initiate Standard Antihypertensive Therapy
Do not discontinue abiraterone for BP <160/100 mmHg. The short-term cardiovascular risk of moderately elevated BP is low and must be balanced against interrupting evidence-based cancer therapy 4.
First-line agent: Calcium channel blocker (amlodipine 5 mg daily) 4
- Start immediately if BP ≥140/90 mmHg
- Reassess in 2 weeks
Second-line: Add ACE inhibitor (perindopril 2 mg daily) OR ARB (losartan 50 mg daily) 4
Third-line: Add thiazide-like diuretic (indapamide 2.5 mg daily) 4
Fourth-line options 4:
- Increase doses of existing antihypertensives
- If serum potassium <4.5 mmol/L and normal renal function, add low-dose spironolactone
- Consider referral to hypertension specialist
Step 3: Consider Switching to Dexamethasone
If hypertension remains refractory despite multiple antihypertensives, switch from prednisone to dexamethasone 0.5-1 mg daily 1. Dexamethasone provides more potent ACTH suppression. The SWITCH study demonstrated 46% of patients achieved PSA decline ≥30% with this strategy, with median PFS of 10.35 months 1. Monitor closely for Cushing syndrome with this approach 5.
Step 4: Alternative - Mineralocorticoid Receptor Antagonist
For patients who cannot tolerate or wish to avoid corticosteroids, eplerenone can replace prednisone 2, 6. A retrospective study of 40 patients showed similar efficacy and toxicity profiles compared to prednisone, though this requires validation 6. Amiloride is preferred over spironolactone or eplerenone in some cases, as high-dose mineralocorticoid antagonists may activate mutant androgen receptors in prostate cancer tissue 7.
Critical Thresholds for Action
BP <160/100 mmHg: Continue abiraterone, initiate/uptitrate antihypertensives 4
BP ≥160/100 mmHg despite treatment: Consider temporary hold of abiraterone, aggressive BP management, and specialist referral 4
BP ≥220 mmHg systolic without end-organ damage: Start amlodipine 5 mg daily, reassess in 2 weeks, continue abiraterone 4
Hypertensive crisis/encephalopathy/malignant hypertension: Permanently discontinue abiraterone, emergency admission required 4
Common Pitfalls to Avoid
- Do not discontinue abiraterone prematurely for manageable hypertension - this compromises cancer outcomes for a treatable side effect
- Do not use prednisone 5 mg once daily - twice-daily dosing is more effective 3
- Do not forget to monitor potassium - hypokalemia occurs in 17-28% and often accompanies hypertension 2, 8
- Do not overlook late-onset toxicity - mineralocorticoid excess can develop or worsen after years of therapy 5
- Do not assume primary aldosteronism - in patients on abiraterone with adrenal incidentalomas, low renin and aldosterone levels indicate drug-induced MES, not autonomous aldosterone production 5
Post-Treatment Considerations
Hypertension typically resolves after abiraterone discontinuation (median 87 days, range 3-236 days) 4. Arrange primary care follow-up within 4 weeks of stopping abiraterone to reassess antihypertensive needs and prevent hypotension from continued treatment 4.